组胺在抽动障碍发病机制中的作用

林端; 刘秀梅

doi:10.11852/zgetbjzz2023-0646

PDF(523 KB)

中国儿童保健杂志 ›› 2024, Vol. 32 ›› Issue (11) : 1236-1240. DOI: 10.11852/zgetbjzz2023-0646

综述

组胺在抽动障碍发病机制中的作用

林端, 刘秀梅

作者信息 +

Research progress on the role of histamine in the pathogenesis of tic disorder

LIN Duan, LIU Xiumei

Author information +

文章历史 +

摘要

组胺作为一种神经调节剂,与抽动障碍(TD)的关系正逐渐成为人们关注的焦点。自从在TD家系中发现组胺合成关键酶组氨酸脱羧酶(HDC)特定基因的突变,组胺参与TD发生的假说在人群及动物模型研究中得到了验证。组胺及其受体参与调节皮质-纹状体-丘脑-皮质(CSTC)环路、神经递质及小胶质细胞介导的神经炎症,影响TD的发生。组胺受体3(H3R)是TD很有前景的药物治疗靶点。本文综述了组胺及其受体在TD发病机制中的作用。

Abstract

The relationship between histamine and tic disorder(TD) as a neuromodulator is gradually gaining attention. Specific gene mutations of histidine decarboxylase(HDC), a key enzyme in histamine synthesis, have been discovered in TD families, verifying the hypothesis that histamine is involved in TD generation in human and animal models. Histamine and its receptors play a role in regulating cortico-striato-thalamo-cortical(CSTC) circuits, neurotransmitters, and microglia-mediated neuroinflammation, which subsequently affect the development of TD. The H3 receptor shows promise as a pharmacotherapeutic target for treating TD. This article reviews the role of histamine and its receptors in the pathogenesis of TD.

导出引用

林端, 刘秀梅. 组胺在抽动障碍发病机制中的作用[J]. 中国儿童保健杂志. 2024, 32(11): 1236-1240 https://doi.org/10.11852/zgetbjzz2023-0646

LIN Duan, LIU Xiumei. Research progress on the role of histamine in the pathogenesis of tic disorder[J]. Chinese Journal of Child Health Care. 2024, 32(11): 1236-1240 https://doi.org/10.11852/zgetbjzz2023-0646

中图分类号： R749.94

参考文献

[1] Deeb W, Malaty IA, Mathews CA. Tourette disorder and other tic disorders[M]//Handb Clin Neurol: 165. Elsevier, 2019: 123-153.
[2] Liu ZS, Cui YH, Sun D, et al. Current status, diagnosis, and treatment recommendation for tic disorders in China[J]. Front Psychiatry, 2020, 11: 774.
[3] Wang X, Liu X, Chen L, et al. The inflammatory injury in the striatal microglia-dopaminergic-neuron crosstalk involved in Tourette syndrome development[J]. Front Immunol, 2023, 14: 1178113.
[4] Naro A, Billeri L, Colucci VP, et al. Brain functional connectivity in chronic tic disorders and Gilles de la Tourette syndrome[J]. Progress in Neurobiology, 2020, 194: 101884.
[5] Qian QQ, Tan QQ, Sun D, et al. A pilot study on plasma and urine neurotransmitter levels in children with tic disorders[J]. Brain Sci, 2022, 12(7): 880.
[6] Ercan-Sencicek AG, Stillman AA, Ghosh AK, et al. L-Histidine decarboxylase and Tourette's syndrome[J]. N Engl J Med, 2010, 362(20): 1901-1908.
[7] Lintas C, Sacco R, Azzarà A, et.al. Genetic dysruption of the histaminergic pathways: A novel deletion at the 15q21.2 locus associated with variable expressivity of neuropsychiatric disorders[J]. Genes, 2022, 13(10): 1685.
[8] Fernandez TV, Sanders SJ, Yurkiewicz IR, et al. Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism[J]. Biol Psychiatry, 2012, 71(5): 392-402.
[9] Rapanelli M, Frick L, Bito H, et al. Histamine modulation of the basal ganglia circuitry in the development of pathological grooming[J]. PNAS, 2017, 114(25): 6599-6604.
[10] Castellan Baldan L, Williams KA, Gallezot JD, et al. Histidine decarboxylase deficiency causes Tourette syndrome: Parallel findings in humans and mice[J]. Neuron, 2014, 81(1): 77-90.
[11] Rapanelli M, Frick LR, Pogorelov V, et al. Dysregulated intracellular signaling in the striatum in a pathophysiologically grounded model of Tourette syndrome[J]. Eur Neuropsychopharmacology, 2014, 24(12): 1896-1906.
[12] Pittenger C. Histidine decarboxylase knockout mice as a model of the pathophysiology of Tourette syndrome and related conditions[M]//Handb Exp Pharmacol, 2017: 189-215.
[13] Jindachomthong K, Yang C, Huang Y, et al. White matter abnormalities in the Hdc knockout mouse, a model of tic and OCD pathophysiology[J]. Front Mol Neurosci, 2022, 15:1037481.
[14] Shitova AD, Zharikova TS, Kovaleva ON, et al. Tourette syndrome and obsessive-compulsive disorder: A comprehensive review of structural alterations and neurological mechanisms[J]. Behav Brain Res, 2023, 453:114606.
[15] Jackson SR, Sigurdsson HP, Dyke K, et.al. The role of the cingulate cortex in the generation of motor tics and the experience of the premonitory urge-to-tic in Tourette syndrome[J]. J Neuropsychol, 2021,15(3):340-362.
[16] Kalanithi PSA, Zheng W, Kataoka Y, et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome[J]. PNAS, 2005, 102(37): 13307-13312.
[17] Liu H, Hua H, Kang T. White matter alterations predict outcomes of comprehensive behavioral intervention for tics in children with Tourette syndrome: A diffusion MRI study[J]. J Psychiatr Res, 2024,175:418-424.
[18] Rapanelli M. The magnificent two: Histamine and the H3 receptor as key modulators of striatal circuitry[J]. Prog Neuro-Psychopharmacol Biol Psychiatry, 2017, 73: 36-40.
[19] Ellender TJ, Huerta-Ocampo I, Deisseroth K, et al. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine[J]. J Neurosci, 2011, 31(43): 15340-15351.
[20] Zhuang QX, Xu HT, Lu XJ, et al. Histamine excites striatal dopamine D1 and D2 receptor-expressing neurons via postsynaptic H1 and H2 receptors[J]. Mol Neurobiol, 2018, 55(10): 8059-8070.
[21] Xu J, Pittenger C. The histamine H3 receptor modulates dopamine D2 receptor-dependent signaling pathways and mouse behaviors[J]. J Biol Chem, 2023, 299(4):104583.
[22] Carthy E, Ellender T. Histamine, Neuroinflammation and Neurodevelopment: A review[J]. Front Neurosci, 2021,15:680214.
[23] Han S, Márquez-Gómez R, Woodman M, et al. Histaminergic control of corticostriatal synaptic plasticity during early postnatal development[J]. J Neurosci, 2020, 40(34): 6557-6571.
[24] Yu J, Yao X, Zhang X, et al. New insights of metabolite abnormalities in the thalamus of rats with iminodiproprionitrile-induced tic disorders[J].Front Neurosci, 2023, 17:1201294.
[25] Augustine F, Singer HS. Merging the pathophysiology and pharmacotherapy of Tics[J]. Tremor and Other Hyperkinetic Movements, 2019, 8(0): 595.
[26] Maia TV, Conceição VA. Dopaminergic disturbances in Tourette syndrome: An integrative account[J]. Biol Psychiatry, 2018, 84(5): 332-344.
[27] Müller-Vahl KR, Berding G, Brücke T, et al. Dopamine transporter binding in Gilles de la Tourette syndrome[J]. J Neurol, 2000, 247(7): 514-520.
[28] Anderson GM. Brain monoamines and amino acids in gilles de la Tourette's syndrome: A preliminary study of subcortical regions[J]. Arch Gen Psychiatry,1992, 49(7): 584.
[29] Rapanelli M, Frick L, Pogorelov V, et al. Histamine H3R receptor activation in the dorsal striatum triggers stereotypies in a mouse model of tic disorders[J]. Transl Psychiatry,2017, 7(1): e1013-e1013.
[30] Varaschin RK, Osterstock G, Ducrot C, et al. Histamine H3 receptors decrease dopamine release in the ventral striatum by reducing the activity of striatal cholinergic interneurons[J]. Neuroscience, 2018, 376: 188-203.
[31] Venkatachalam K, Eissa N, Awad MA, et al. The histamine H3R and dopamine D2R/D3R antagonist ST-713 ameliorates autism-like behavioral features in BTBR T+tf/J mice by multiple actions[J]. Biomed Pharmacother, 2021, 138:111517.
[32] Ma Q, Jiang L, Chen H, et al. Histamine H₂ receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia[J]. PNAS, 2023, 120(9): e2207003120.
[33] Dere E, De Souza-Silva MA, Spieler RE, et al. Changes in motoric, exploratory and emotional behaviours and neuronal acetylcholine content and 5-HT turnover in histidine decarboxylase-KO mice[J]. Eur J Neurosci, 2004, 20(4): 1051-1058.
[34] Pfanzagl B, Pfragner R, Jensen-Jarolim E. Histamine via histamine H1 receptor enhances the muscarinic receptor-induced calcium response to acetylcholine in an enterochromaffin cell model[J]. Clin Exp Pharmacol P, 2022, 49 (10): 1059-1071.
[35] Nirogi R, Benade V, Daripelli S, et al. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: Pharmacological and neurochemical characterisation[J]. Psychopharmacology, 2021, 238 (6): 1495-1511.
[36] Johnson KA, Worbe Y, Foote KD, et al. Tourette syndrome: Clinical features, pathophysiology, and treatment[J]. Lancet Neurol, 2022, 22 (2): 147-158.
[37] Kumar A, Williams MT, Chugani HT. Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and tourette syndrome: A positron emission tomographic(PET) study using¹¹ C-[R]-PK11195[J]. J Child Neurol, 2015, 30(6): 749-756.
[38] Yanhui C. Neuroinflammation in a rat model of Tourette Syndrome[J]. Front Behav Neurosci, 2022, 16.
[39] Dong H, Wang Y, Zhang X, et al. Stabilization of brain mast cells alleviates LPS-induced neuroinflammation by inhibiting microglia activation[J]. Front Cell Neurosci, 2019, 13:191.
[40] Barata-Antunes S, Cristóvão AC, Pires J, et al. Dual role of histamine on microglia-induced neurodegeneration[J].Bba-mol Basis Dis, 2017, 1863 (3): 764-769.
[41] Frick L, Rapanelli M, Abbasi E, et al. Histamine regulation of microglia: Gene-environment interaction in the regulation of central nervous system inflammation[J]. Brain Behav Immun, 2016, 57: 326-337.
[42] Zhang W, Zhang X, Zhang Y, et al. Histamine induces microglia activation and the release of proinflammatory mediators in rat brain via H1R or H4R[J]. J Neuroimmune Pharmacol, 2020, 15(2): 280-291.
[43] Zhu J, Qu C, Lu X, et al. Activation of microglia by histamine and substance P[J]. Cell Physiol Biochem,2014, 34(3): 768-780.
[44] Ferreira R, Santos T, Gonçalves J, et al. Histamine modulates microglia function[J]. J Neuroinflammation, 2012, 9: 90.
[45] Olah M, Biber K, Vinet J, et al. Microglia phenotype diversity[J]. CNS Neurol Disord Drug Targets,2011,10(1): 108-118.
[46] Wolf SA, Boddeke HWGM, Kettenmann H. Microglia in physiology and disease[J]. Annu Rev Physiol, 2017, 79(1): 619-643.
[47] Godar SC, Mosher LJ, Di Giovanni G, et al. Animal models of tic disorders: A translational perspective[J]. J Neurosci Meth, 2014, 238: 54-69.
[48] Gober HJ, Li KH, Yan K, et al. Hydroxyzine use in preschool children and its effect on neurodevelopment: A population-based longitudinal study[J]. Front Psychiatry, 2022, 12: 721875.
[49] Rapanelli M, Frick L, Jindachomthong K, et al. Striatal signaling regulated by the H3R histamine receptor in a mouse model of tic pathophysiology[J]. Neuroscience, 2018, 392: 172-179.
[50] Wang J, Liu B, Sun F, et al. Histamine H3R antagonist counteracts the impaired hippocampal neurogenesis in Lipopolysaccharide-induced neuroinflammation[J]. Int Immunpharmacol, 2022, 110:109045.
[51] Hartmann A, Worbe Y, Arnulf I. Increasing histamine neurotransmission in Gilles de la Tourette syndrome[J]. J Neurol, 2012, 259(2): 375-376.
[52] Ricketts EJ, Swisher V, Greene DJ, et al. Sleep disturbance in Tourette＇s disorder: Potential underlying mechanisms[J]. Curr Sleep Med Rep, 2023, 9(1):10-22.
[53] Pittenger C. The histidine decarboxylase model of tic pathophysiology:A new focus on the histamine H₃ receptor[J]. Br J Pharmacol,2020, 177(3): 570-579.
[54] Zhou P, Homberg JR, Fang Q, et al. Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of parkinson-like pathology and behaviour in a rat model[J]. Brain Behav Immun, 2019, 76: 61-73.